EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Early Hemostatic Treatment Could Improve 30‐Day Survival After Spontaneous Rupture of Hepatocellular Carcinoma

Apolline Commin iD, Chloé Metivier, Manon Allaire iD, Jean Lubrano, Amandine Claudinot, Audrey Coilly iD, Marc-Antoine Allard, Charles Roux, Olivier Scatton, Jean Charles Nault, Olivier Sutter, Nathalie Ganne-Carrié und 11 weitere

Liver International · 2025

DOI: 10.1111/liv.70332 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, 2025. Verfasst von Apolline Commin und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatogastroenterology, University Hospital, Caen, France. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hemostatic Techniques, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Spontaneous rupture of hepatocellular carcinoma (SRHCC) presents a critical clinical challenge, with early haemostasis often difficult to achieve and limited data available on subsequent treatment strategies. This study aims to evaluate whether the initial hemostatic approach influences early prognosis and facilitates further treatment of HCC.

Methods

This retroprospective multicentric cohort included patients with SRHCC since 2008. Cox and Kaplan–Meier models analysed factors associated with overall survival (OS).

Results

112 patients with SRHCC were included. Hemostatic treatment was administered in 54.4% of cases (83.6% embolization, 9.8% surgery and 6.6% embolization plus surgery). The 30‐day mortality rate was 28.6%. Factors associated with 30‐day mortality included ALBI score > 2 (HR = 4.23; p = 0.001), shock (HR = 2.37; p = 0.029), acute kidney injury (HR = 4.40; p = 0.003), and BCLC stage C/D (HR = 14.29; p = 0.010). Early hemostatic intervention was associated with improved 30‐day survival (HR = 0.42; p = 0.033). Palliative care was initiated in 27% of patients (10% after embolization and 17% upon admission). One‐third of patients received subsequent HCC treatment after a median of 84 days [IQR: 39–176] (55.3% surgery and 18.4% systemic therapy). Among these, 63% ( n = 24) had undergone early hemostatic treatment. The one‐year OS rate was 39.3%, the median follow‐up duration was 136 days (95% CI: 20.3–739.5), and the median OS was 6.6 ± 4.1 months (95% CI: 0–14.8). Delayed HCC treatment following rupture significantly improved OS (HR = 0.35; 95% CI: 0.20–0.61; p < 0.001), particularly when surgery was performed ( p < 0.0001).

Conclusion

Our results suggest that early hemostatic treatment could be beneficial after spontaneous rupture of HCC in well compensated patients. Trial Registration NCT06505291

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularHemostatic TechniquesLiver NeoplasmsAgedFemaleHumansMaleMiddle AgedEmbolization, TherapeuticHemostaticsKaplan-Meier EstimateProportional Hazards ModelsRetrospective StudiesRupture, SpontaneousTreatment Outcome

Stichwörter der Autor:innen

atezolizumabbevacizumabchemoembolizationembolizationhaemorrhagehaemostasisruptured hepatocellular carcinomasorafenibsurgery

Substanzen

Hemostatics

Autor:innen und Institutionen

  • Department of Hepatogastroenterology, University Hospital, Caen, France.
  • Department of Hepatogastroenterology, La Pitié Salpétrière Hospital (APHP), Paris, France.
  • Department of Hepatobiliary Surgery, University Hospital, Caen, France.
  • Department of Radiology, University Hospital, Caen, France.
  • Department of Hepatogastroenterology, Paul Brousse Hospital (APHP), Paris, France.
  • Department of Hepatobiliary Surgery, Paul Brousse Hospital (APHP), Paris, France.

ORCID-Profile: Apolline Commin, Manon Allaire, Audrey Coilly, Isabelle Ollivier-Hourmand

Zitieren

APA

Commin, A., Metivier, C., Allaire, M., Lubrano, J., Claudinot, A., Coilly, A., Allard, M. A., Roux, C., Scatton, O., Nault, J. C., Sutter, O., Ganne-Carrié, N., Ngo, T. V., Goff, V. L., Ali, Z. B., Tedlaouti, H., Papin, J., Habireche, M., Lebedel, L., …, & Ollivier-Hourmand, I. (2025). Early Hemostatic Treatment Could Improve 30‐Day Survival After Spontaneous Rupture of Hepatocellular Carcinoma. Liver International. https://doi.org/10.1111/liv.70332

Vancouver

Commin A, Metivier C, Allaire M, Lubrano J, Claudinot A, Coilly A, et al. Early Hemostatic Treatment Could Improve 30‐Day Survival After Spontaneous Rupture of Hepatocellular Carcinoma. Liver International. 2025. doi:10.1111/liv.70332

BibTeX
@article{Commin2025,
  author = {Commin, Apolline and Metivier, Chloé and Allaire, Manon and Lubrano, Jean and Claudinot, Amandine and Coilly, Audrey and Allard, Marc-Antoine and Roux, Charles and Scatton, Olivier and Nault, Jean Charles and Sutter, Olivier and Ganne-Carrié, Nathalie and Ngo, Thuy Vi and Goff, Valérie Le and Ali, Zeineb Ben and Tedlaouti, Husni and Papin, Josephine and Habireche, Marion and Lebedel, Louise and Pérignon, Claire and Dao, Thông and Morello, Rémy and Ollivier-Hourmand, Isabelle},
  title = {Early Hemostatic Treatment Could Improve 30‐Day Survival After Spontaneous Rupture of Hepatocellular Carcinoma},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70332}
}
Kostenlos starten →